Summary
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. has a governing agreement with QIAGEN Manchester Limited. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
History
HTG Molecular Diagnostics was founded in Tucson, Arizona in 2002 and went public in November, 2014 on the NASDAQ Global Market. It has a 114,000-square-foot production and distribution facility in Tucson, Arizona.The company closed its initial public offering on November 6, 2014, which raised $37.5 million.On October 29, 2015, HTG Molecular Diagnostics announced that it had received a milestone payment of $5 million from Merck & Co as part of their co-development initiative. On November 5, 2016, the company announced that its HTG EdgeSeq Oncology Kit had been approved by New York State Department of Health for use in the state of New York.
Mission
HTG Molecular Diagnostics’ mission is to drive a transformation in healthcare, enabling physicians and researchers to get precision medicine insights rapidly, accurately, and affordably.
Vision
HTG Molecular Diagnostics's vision is to create an integrated workflow of solutions to provide precision medicine insights for the diagnosis, treatment and monitoring of complex diseases.
Key Team
Dr. Patrick C. Roche (Sr. VP of R&D)
Ms. Laura Lee Godlewski (Sr. VP of Fin. & Admin.)
Dr. Debra A. Gordon (Sr. VP & Chief Legal Counsel)
Dr. Christina M. Carruthers Ph.D. (VP of Target Strategy & Early Devel.)
Dr. Stephen A. Barat Ph.D. (Sr. VP of Therapeutics)
Debrah Thompson (VP of Scientific Innovation)
Recognition and Awards
HTG Molecular Diagnostics has been recognized for accomplishments in product innovation. In 2017, HTG Molecular Diagnostics was granted Frost & Sullivan’s 2017 North American Molecular Diagnostics Technology Innovation Leadership Award. They were also awarded the prestigious “Technology Pioneer 2018” Award from the World Economic Forum. In 2019, HTG Molecular Diagnostics was granted the 2019 Molecular Diagnostics & Pharmacogenomics Innovation Leadership Award.
References
